Genus Claims and Species Novelty in Indian Pharmaceutical Patents: The Portfolio Warning Inside Intra Cellular Therapies
A patent family can become its own most dangerous prior art, and most pharmaceutical patent teams discover this too late to address it. The drafting logic that creates the problem is entirely understandable at the time
Read More